Insulet Co. (NASDAQ:PODD) Shares Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. increased its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 5.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 153,416 shares of the medical instruments supplier's stock after purchasing an additional 8,301 shares during the quarter. Nomura Asset Management Co. Ltd. owned 0.22% of Insulet worth $35,708,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. MML Investors Services LLC lifted its stake in shares of Insulet by 9.3% in the 3rd quarter. MML Investors Services LLC now owns 2,655 shares of the medical instruments supplier's stock worth $618,000 after acquiring an additional 225 shares during the period. Orion Portfolio Solutions LLC raised its holdings in Insulet by 86.2% during the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier's stock worth $1,822,000 after purchasing an additional 3,623 shares in the last quarter. XTX Topco Ltd acquired a new stake in Insulet in the third quarter valued at about $1,478,000. iA Global Asset Management Inc. boosted its holdings in Insulet by 98.3% in the 3rd quarter. iA Global Asset Management Inc. now owns 2,058 shares of the medical instruments supplier's stock valued at $479,000 after purchasing an additional 1,020 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC increased its position in Insulet by 12.2% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 15,062 shares of the medical instruments supplier's stock worth $3,506,000 after purchasing an additional 1,640 shares during the period.

Analyst Ratings Changes

A number of brokerages recently weighed in on PODD. Citigroup upped their price objective on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Piper Sandler increased their price target on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Canaccord Genuity Group raised their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research note on Monday. BTIG Research upped their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Finally, Raymond James lifted their price target on shares of Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Insulet has a consensus rating of "Moderate Buy" and an average price target of $255.60.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $9.67 on Tuesday, hitting $274.79. The company had a trading volume of 781,518 shares, compared to its average volume of 764,055. The company has a market cap of $19.28 billion, a PE ratio of 47.05, a PEG ratio of 4.06 and a beta of 1.21. The business has a 50 day moving average of $248.93 and a 200 day moving average of $218.65. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.